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Objective: To describe clinical features of epilepsy secondary to Malformation of Cortical Development
(MCD) in a series of adult patients.
Materials and methods: We searched our database for all cases with conﬁrmed epilepsy and MCD and
included in the study only those with complete data. Mean age, sex, age at seizure onset (ASO), seizure
types, abnormal neurological exam (ANE), mental retardation, family history, gestational or perinatal
insults (G-PI), interictal EEG and response to treatment were analyzed. Cases were classiﬁed into the 3
main groups (G) according to the Barkovich classiﬁcation (BC) and then compared: (G1) ‘‘malformations
due to abnormal cell proliferation’’, (G2) ‘‘malformations due to abnormal migration’’ and (G3)
‘‘malformations due to abnormal cortical organization’’.
Results: We identiﬁed 152 (5.06%) patients with MCD from a total of 3000 with epilepsy. In total, 138
patients with complete medical data were included in this study. The mean age of patients was 36.2
years, 52.2% were female, the mean ASO was 12.3 years, 5.1% of cases had a positive family history and
21% had G-PI. An ANE was observed in 21% and mental retardation in 31.9%. Most of the patients (84.8%)
had refractory epilepsy. The distribution of cases according to the BC was: 51.4% in G1, 28.9% in G2 and
19.6% in G3. Comparing the 3 groups, we found that an ANE was statistically more frequent in G3 and was
present in 70.4% of cases.
Conclusion: Our series of adult patients with epilepsy and MCD suggests that MCD are identiﬁed as
commonly in a developing country as in previous ‘‘ﬁrst world’’ series. Neurological deﬁcits were more
common in the subgroup of patients with polymicrogyria and schizencephaly (BC Group 3).
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Malformations of cortical development (MCD) are responsible
for a wide spectrum of clinical manifestations that include
epilepsy, mental retardation and neurological deﬁcits.1,2 MCD
are considered the second most common cause of medically
refractory partial epilepsy in adults after hippocampal sclerosis.3
Diagnosis of MCD has notably been improved in the past 2 decades
as a result of advances in modern imaging, especially magnetic
resonance imaging (MRI), and genetics.4 Epilepsies that were
considered cryptogenic in the past are now recognized as
secondary to MCD.
The anatomical and histological subtypes of MCD depend on the
severity of the insult or the genetic anomaly affecting the normal
development of the brain and the moment that the failure
occurred.5,6 A variety of etiologies have been related to MCD,* Corresponding author at: Diaz Velez 3769 88A, Buenos Aires 1200, Argentina.
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doi:10.1016/j.seizure.2012.03.009including genetic defects and intrauterine insults (infections,
traumatisms, strokes or drug exposure). Some insults could also
have happened in postnatal life.6,7
In 1996, Barkovich et al.8 proposed a classiﬁcation of MCD based
on the ﬁrst point at which the developmental process is disturbed.
The Barkovich classiﬁcation (BC) categorizes patients into 3 main
groups: Group 1 includes ‘‘malformations due to abnormal cell
proliferation’’, Group 2 includes ‘‘malformations due to abnormal
migration’’ and Group 3 includes ‘‘malformations due to abnormal
cortical organization’’. The BC was updated in 2001 and 2005, due
to the constant advances in knowledge.9,10
In this article, we describe a series of adult patients with epilepsy
associated with MCD who were assessed at an epilepsy center in the
city of Buenos Aires. All patients included in this study were
classiﬁed into 1 of the 3 main groups deﬁned in BC and comparisons
were made of the clinical ﬁndings in the different groups.
The main purpose of this study was to investigate the clinical
features of MCD in our population and compare our results with
those of previous reports on the subject, taking into account that
our center is located in a developing country and that there are not
many reports of this pathology in this region.vier Ltd. All rights reserved.
Table 1
Clinical features.
Mean Range
Age at last follow up (y) 36.2 18–77
Age of seizure onset (y) 12.3 0–66
Duration of epilepsy (y) 23.9 3–60
N = 138 %
Female gender 72 52.2
Family history 7 5.1
History of perinatal injury 21 15.2
History of spams/West syndrome 6 4.3
Neurological deﬁcit 29 21.0
Mental retardation 44 31.9
Focal seizures 138 100
Secondary generalized seizures 102 73.9
Temporal lobe epilepsy 41 29.7
Frontal lobe epilepsy 39 28.3
Parietal lobe epilepsy 16 11.6
Occipital lobe epilepsy 9 6.5
Seizures corresponding to more than 1 lobe 27 19.6
Seizure not indicative of one lobe 6 4.3
EEG with epileptiform discharges 100 72.5
EEG with bilateral discharges 75 54.9
Drug resistant epilepsy 117 84.8
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We retrospectively reviewed the clinical records of adult
patients (18 years of age) that visited the Epilepsy Centre of the
Ramos Mejı´a Hospital in the city of Buenos Aires and whose ﬁrst
evaluations were between 1985 and 2007. From our standardized
clinical database, we included all cases with conﬁrmed diagnosis of
epilepsy and whose MRI had identiﬁed MCD. A standardized 1.5 T
MRI study that included T1- and T2-weighted, inversion recovery
and ﬂuid-attenuated inversion recovery acquisitions was used.
Patients who were ﬁrst observed in the era before MRI had their
diagnosis of MCD later during their follow up, when MRI became
available. We only included cases in which the opinion of two
different neurologists (one of them specialized in imaging
techniques) agreed on the diagnosis. Cases that were lost to
follow up or that had missing clinical, epidemiological or interictal
EEG data were excluded from the study.
It is important to explain the referral pattern of our center to
understand the composition of this patient population. The center
in this study belongs to a public hospital, which means that, even
though any patient with suspected epilepsy could ask for an
appointment, most of the patients lack health insurance and have
low income. In addition, this center is considered a referral center
and receives complex cases transferred from others health centers
all over the country. Only adult patients are treated in this center
because patients under 18 years old are generally assessed by
pediatric neurologists in other specialized pediatric hospitals.
We analyzed the following variables: sex, age at last follow up,
age at seizure onset, seizure types, epilepsy syndromes, presence of
an abnormal neurological exam, mental retardation, family history
of epilepsy or neurological disease (ﬁrst degree relatives) and the
existence of prenatal (intrauterine) or perinatal insults. A patient
was considered mentally retarded when his IQ was below 80
according to the WAIS test (borderline deﬁciency or a lower
degree). Seizures were classiﬁed as focal or generalized according
to the last report of the International League Against Epilepsy
(ILAE) Commission on Classiﬁcation and Terminology, 2005–
200911 and epilepsy syndromes, based in semiology, and were
divided into temporal, frontal, parietal or occipital lobe epilepsy.12
Interictal EEG recordings were also evaluated and classiﬁed as
normal, abnormal with epileptic discharges or abnormal without
epileptiform discharges. Epileptiform discharges were divided into
focal-regional or multifocal-bilateral discharges. Video EEG
recordings were performed in some of the refractory epileptic
patients to establish the epileptogenic zone and whether they were
candidates for surgery.
To classify whether patients were responsive to treatment, we
used the latest deﬁnition proposed by the ILAE. According to this
deﬁnition, patients were considered to have drug resistant
epilepsy when at least two adequate and tolerated antiepileptic
drug (AED) schedules failed to achieve sustained seizure free-
dom.13 Each AED was used at the highest tolerated dose and AED
levels, available for the classic drugs, were measured for different
purposes (to establish adherence, toxicity, etc.).
In accordance with ILAE Treatment Guidelines,14 carbamaze-
pine is most often selected in our center as the ﬁrst choice for
adults with partial onset seizures. Monotherapy is always seen as
the best alternative whenever possible, and newer drugs are
usually used as add-on therapies.
A detailed assessment of MRI features allowed us to determine
the MCD subtype according to BC scheme,10 which can be
summarized by 3 main groups:
Group 1: ‘‘malformations due to abnormal cell proliferation’’
Group 2: ‘‘malformations due to abnormal migration’’
Group 3: ‘‘malformations due to abnormal cortical organization’’In the BC, focal cortical dysplasias (FCDs) are included in Group
1 only when balloon cells are present, and other FCDs are
incorporated into Group 3. In this study, cases with FCD were all
classiﬁed as belonging to Group 1, assuming that most of our cases
with FCD correspond to subtype IIb, according to the new ILAE
classiﬁcation15 and Palmini et al.’s classiﬁcation,16 as they are
easier to detect by MRI.
We classiﬁed patients as having dual pathology when the MCD
was associated with hippocampal sclerosis (HS).
After classifying patients in these 3 groups, we made a
comparison of their clinical presentation.
All evaluated data were recorded in a database (Microsoft Excel
v. 2003) and then exported to SPSS version 11.5 software (IBM,
USA) for statistical analysis. One-way Anova tests were used to
calculate the p-values for continuous quantitative variables, and
Fisher exact tests were used to calculate the p-values for
qualitative variables. A p-value lower than 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Clinical and epidemiological data: (see Table 1)
A total of 152 patients with a diagnosis of epilepsy and MCD, as
shown by MRI, were identiﬁed from approximately 3000 clinical
records (frequency of 5.06%). This study included 138 of these 152
patients. The remaining 14 patients were excluded from the study
due to incomplete data or loss to follow up. The mean age at last
follow up in the study population was 36.2 years (range 18–77),
52.2% were female and 5.1% of the cases had a family history of
epilepsy or other neurological disease. An abnormal neurological
exam was found in 21% of patients, and 31.9% of the patients
presented with some degree of mental retardation (IQ less than
80). A gestational or a perinatal insult (e.g., perinatal anoxia,
preterm labor) occurred in 15.2% of patients.
3.2. Types of seizures and epilepsy data: (see Table 1)
The mean age at seizure onset was 12.3 years (range 0–66), with
23% of cases starting their epilepsy in adulthood (18 years of age),
and the mean duration of epilepsy was 23.9 years (range 3–60). A
history of epileptic spasms or West syndrome was reported to be
Table 2
Subtypes included in each group of MCD.
Group 1 Subtype N Group 2 Subtype N Group 3 Subtype N
N = 71 FCD 34 N = 40 PNH 22 N = 27 SCHI 10
FCD plus GNTa 10 Sub H 7 PMG 17
Dual Patb 10 Mix H 4 -BPP 6
GNT 7 Dual Patc 5 -BPOP 1
TS 7 DC 2 -UP 10
HME 1
FHME vs. FCD 2
FCD: focal cortical dysplasia; FCD plus GNT: focal cortical dysplasia plus glioneuronal tumor; Dual Pat: dual pathology; GNT: glioneuronal tumor; TS: tuberous sclerosis;
HME: hemimegalencephaly; FHME vs. FCD: focal hemimegalencephaly vs. focal cortical dysplasia; PNH: periventricular nodular heterotopia; Sub H: subcortical heterotopia;
Mix H: mixed forms of heterotopia; DC: doble cortex or subcortical band heterotopia; SCHI: schizencephaly; PMG: polymicrogyria; BPP: bilateral perisylvian polymicrogyria;
BPOP: bilateral parieto occipital polymicrogyria; UP: unilateral polymicrogyria.
a Co-existence of MRI features of both entities in the same area.
b Co-existence of MCD with hippocampal sclerosis: 1 patient had a lesion classiﬁed as FCD plus GNT and the other nine patients had FCD.
c In group 2, dual pathology consisted of PNH plus hippocampal sclerosis.
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them belonging to Group 1 of BC scheme (3 with diagnosis of FCD
and 3 with tuberous sclerosis).
All patients developed focal seizures, and 73.9% of cases
experienced focal evolving to bilateral seizures (or secondary
generalized tonic–clonic seizures) at least once during evolution.
Semiology of these focal seizures can be divided into the following
epileptic syndromes: temporal lobe epilepsy in 41 patients, frontal
epilepsy in 39 patients, parietal epilepsy in 16 patients, occipital
lobe epilepsy in 9 patients, seizures corresponding to more than
one lobe in 27 patients and semiology not indicative of a particular
lobe in 6 patients.
3.3. EEG recordings
Interictal EEG recordings were normal in 27.5% of cases and
showed epileptiform discharges in 72.5% of cases. Of these
abnormal EEGs, 54.9% showed bilateral or multifocal discharges,
and 45.1% had focal or regional epileptiform activity.
Video EEG monitoring was performed in 29 patients due to the
presence of refractory epilepsy and was used to conﬁrm the focal
onset of seizures, deﬁne the epileptogenic zone and to evaluate
therapeutic options. Most of these patients belonged to Group 1.
This study was not performed in cases that were considered bad
candidates for resective surgery; for example, patients with
bilateral or non-resectable malformations.
3.4. Response to treatment and epilepsy surgery
According to the deﬁnition proposed by the ILAE,12 84.8% of
patients had drug resistant epilepsy because they failed to achieve
sustained seizure freedom with at least two adequate and
tolerated AED schedules.
Of the patients that achieved complete seizure control, 42.85%
(9 out of 21) were on monotherapy. With regard to refractory
patients, all of them were on polytherapy, 38.45% (45 out of 117)
having tried 5 or more AEDs in different combinations.
Surgery was performed in only 9 patients. All of the operated
patients belonged to Group 1. The preoperative MRI in these
patients allowed the following diagnoses: 4 patients had FCD
type IIB, 3 patients had dual pathology (FCD type IIb + HS), 1
patient had a glioneuronal tumor (GNT) and 1 patient had
tuberous sclerosis (TS). In 8 of these patients, 5.7% of the total
population included in this study, surgery was performed with
the objective of ameliorating epilepsy. The patient with the
diagnosis of TS was operated on with the goal of resecting a
giant cell tumor. The 8 patients that underwent epilepsy surgery
have now had at least two years of follow up after surgery (mean
6.8 years). The mean age at surgery was 33.44 years (range:19–62). Lesions were located in the temporal lobe in 5 cases and
in the frontal lobe in 3 cases. Chronic stereo-electroencepha-
lography was used in 3 patients to determine with more
precision the epileptogenic zone. 5 of these 8 operated cases
(62.5%) were free of all types of seizures (Engel 1A) on their last
follow up visit. Histopathological ﬁndings conﬁrmed what MRI
in all of the operated patients suspected: 4 patients with FCD
type IIb, 3 patients with dual pathology (FCD type IIb + HS), 1
Dysembryoplastic Neuroepithelial Tumor (DNET) and 1 giant
cell tumor.
3.5. Comparison of the different subtypes of MCD
The distribution of cases according to BC was as follows: 71
patients (51.4%) belonged to Group 1 (malformations due to
abnormal cell proliferation); 40 patients (28.9%) belonged to Group
2 (malformations due to abnormal migration) and 27 patients
(19.6%) belonged to Group 3 (malformations due to abnormal
cortical organization). The different subtypes included in each
group are shown in Table 2.
Cases in Group 1 were diagnosed as having FCD (see Fig. 1), dual
pathology, GNT, FCD plus GNT, TS, hemimegalencephaly or focal
hemimegalencephaly vs. FCD.
Group 2 included patients with periventricular nodular
heterotopia (PNH) (see Fig. 2), subcortical heterotopia, mixed
forms of heterotopia, dual pathology and double cortex.
Group 3 included cases with polymicrogyria (PMG) and
schizencephaly.
The following deﬁnitions provide clariﬁcation on some of these
diagnoses:
- Focal cortical dysplasia: conventional MRI criteria that are
suggestive of FCD include gyration anomalies, focal thickening
of the cortex, blurring of the gray-white matter junction and
abnormal cortical and subcortical signal intensity.17,18 We
included all FCDs in Group 1 with the assumption that most of
our FCD correspond to subtype IIb, according to the new ILAE
classiﬁcation14 and Palmini et al. classiﬁcation,16 as this subtype
could be easier to detect by MRI. For example, the ‘‘transmantle
sign’’, (a white matter signal alteration that goes from crown of a
gyrus or bottom of a sulcus toward the ventricle) ﬁrst described
by Barkovich in 1997, is almost exclusively found in FCD Type
IIb.15 Transmantle characteristics were found in 16 of 34 of our
FCD patients. However, a certain diagnosis is possible only with
histopathological data, which were available in only a few of the
patients of our series.
- Dual pathology: according to Blu¨mcke et al.15 this term refers only
to patients with hippocampal sclerosis who have a second
principal lesion affecting the brain (which may be located outside
Fig. 1. (A) Inversion recovery (IR) and (B) ﬂuid attenuation inversion recovery (FLAIR) MRI sequence showing a transmantle focal cortical dysplasia in the superior and middle
frontal gyrus at the right side.
Fig. 2. IR sequence of a patient with periventricular nodular heterotopia.
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FCD or a GNT. It should be distinguished from FCD Type IIIa with
histopathologically conﬁrmed architectural abnormalities in theTable 3
Localization and extent of lesions in each group.
MCD subtypesa Multilobar
involvement
Frontal 
involvem
Group 1
(n = 71)
FCD (n = 34) 4 24 
Dual Pat (n = 10) 4 0 
DCF plus GNT (n = 10) 2 1 
GNT (n = 7) 1 1 
TS (n = 7) 7 7 
HM (n = 1) 1 1 
FHM vs. D (n = 2) 1 1 
Group 2
(n = 40)
PNH (n = 22) NA NA 
Sub H (n = 8) 5 2 
Mix H (n = 4) 3 1 
Dual Pat (n = 4) NA NA 
DC (n = 2) 2 2 
Group 3
(n = 27)
SCHI (n = 10) 4 5 
PMG (n = 17) 6
-BPP (n = 6) 1 6 
-BPOP (n = 1) 6 0 
-UP (n = 10) 7 
NA: not applicable. Note: The sum of the boxes can be more than the total as cases ca
a MCD subtypes: abbreviations are the same that those given in Table 2.temporal lobe associated with hippocampal sclerosis. This last
type of FCD was not included in this study. In Group 2, patients
with dual pathology had HS and PNH.
- Glioneuronal tumor: These tumors are associated with disordered
cortex, so they are included in Group 1 of the BC in the neoplastic
subcategory (1C2). The tumor subtypes included are gang-
lioglioma, gangliocytoma and dysembryoplastic neuroepithelial
tumor.
- Focal cortical dysplasia plus glioneuronal tumor: We classiﬁed in
this category those cases with mixed characteristics observed in
the MRI (features of FCD together with GNT ﬁndings in the same
area), although we did not have histological conﬁrmation. In the
ILAE classiﬁcation of FCD, these cases would correspond to type
IIIb: cortical lamination abnormalities adjacent to a glioneuronal
tumor.15
- Focal hemimegalencephaly vs. focal cortical dysplasia: The dividing
line between an FCD and hemimegalencephaly (HME) is not
always obvious; therefore, it can sometimes be difﬁcult to
distinguish these two entities by means of an MRI alone. These
two malformations are often considered as part of a spectrum, in
which HME would be a severe form of cortical dysplasia.
The localization and extent of the lesions in each group are
given in Table 3. Multi-lobar involvement was higher in Group 2lobe
ent
Temporal lobe
involvement
Parietal lobe
involvement
Occipital lobe
involvement
12 3 1
10 3 1
7 1 3
6 0 1
5 4 5
1 1 1
1 0 1
NA NA NA
7 5 3
4 2 2
NA NA NA
2 2 2
5 5 0
6 0 0
0 1 1
5 5 4
n have more than 1 lobe involvement.
Fig. 3. (A) axial T2-weighted image and (B) coronal IR sequence showing a case with bilateral perisylvian polymicrogyria.
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of 14, excluding PNH in which this concept cannot be applied), 63%
in Group 3 (17 out of 27) and 28% of in Group 1 (20 out of 71).
Epileptic syndromes in the different groups (see Table 4):
- In Group 1, excluding the patients with TS which usually have
multifocal lesions, (n = 64), epileptic syndromes according to
semiology were as follows: frontal lobe epilepsy was present in
23 patients, temporal lobe epilepsy was present in 23 patients,
parietal lobe epilepsy was present in 7 patients, occipital lobe
epilepsy was present in 3 patients and seizures corresponding to
more than 1 lobe were present in 6 patients. Semiology was not
indicative for a particular lobe in 2 patients. In the case of TS
patients (n = 7): 4 had semiology of frontal lobe epilepsy and 3
had more than 1 seizure type.
- In Group 2 (n = 40), seizure semiology had the following
distribution: 14 patients had seizures with onsets corresponding
to more than 1 lobe, 12 patients had semiology of temporal lobe
epilepsy, 5 patients had occipital lobe epilepsy, 3 patients had
frontal lobe epilepsy, 4 patients had parietal lobe epilepsy and
seizures not indicative for a particular lobe were found in 2
patients.
- In Group 3 (n = 27), seizure semiology had the following
distribution: frontal lobe epilepsy was present in 9 patients,Table 4
Comparison of epidemiological, clinical and electroencephalographic ﬁndings in the 3 
Group 1 (n = 71) 
Age at last follow up (y) 36.8 (20.2–77.1) 
Age at seizure onset (y) 11.9 (0.1–66) 
Mean duration of epilepsy (y) 24.9 (6.74–60.1) 
Female gender 32 (44%) 
Family history 6 (8.4%) 
History of West Syndrome 6 (8.4%) 
History of perinatal injury 8 (11.2%) 
Mental retardation 23 (32.4%) 
Neurological deﬁcit 5 (7.0%) 
Secondary generalized seizures 53 (74.6%) 
Temporal lobe epilepsy 23 (32.4%) 
Frontal lobe epilepsy 27 (38.0%) 
Parietal lobe epilepsy 7 (9.8%) 
Occipital lobe epilepsy 3 (4.2%) 
Seizures corresponding to more than 1 lobe 9 (12.7%) 
Seizure not indicative of one lobe 2 (2.8%) 
Epileptiform discharges in EEG 48 (67.6%) 
EEG with bilateral discharges 33 (46.5%) 
Refractory epilepsy 60 (84.5%) 
* p = 0.0001.temporal lobe epilepsy was present in 6 patients, parietal lobe
epilepsy was present in 5 patients, occipital lobe epilepsy was
present in 1 patient, 4 patients had seizures corresponding to
more than 1 lobe and 2 patients had non-localized semiology.
Comparing epidemiological, clinical and electroencephalo-
graphic data between the 3 groups (see Table 4), just one variable
reached statistical signiﬁcance: the existence of a neurological
deﬁcit. This variable was higher in Group 3 (p = 0.0001) and was
present in 70.4% of the cases included in this group.
4. Discussion
In this article, we report a series of adult patients with
symptomatic partial epilepsy secondary to MCD who were assisted
in a specialized epilepsy center in the city of Buenos Aires. We
found 152 patients with this diagnosis and included 138 of these
patients in the study. Taking into account the active population of
patients with epilepsy who attended our center in the speciﬁed
period (near 3000 patients), the frequency of presentation of MCD
was of approximately 5%. This is similar to what was reported in
other patient series, although the true incidence of MCD is not
known. In the diagnosis of focal epilepsy, MCD prevalence ranges
between 3% and 25% depending on the varying selection criteriagroups.
Group 2 (n = 40) Group 3 (n = 27)
37.1 (1.7–66.3) 36.2 (18.27–59.7)
12.9 (0.8–32) 12.5 (0.7–32)
24.4 (3.0–52.23) 20.6 (7.42–47.7)
27 (66%) 13 (52%)
1 (2.4%) 0
0 0
7 (17.5%) 6 (4.3%)
10 (25%) 11 (40.7%)
5 (12.5%) 19 (70.4%)*
32 (80%) 15 (62.9%)
12 (30%) 6 (22.2%)
3 (7.5%) 9 (33.3%)
4 (10.0%) 5 (18.5%)
5 (12.5%) 1 (3.7%)
14 (35%) 4 (14.8%)
2 (5.0%) 2 (7.4%)
31 (77.5%) 21 (77.8%)
16 (40%) 6 (22.2%)
35 (87.5%) 22 (81.4%)
C.E. Papayannis et al. / Seizure 21 (2012) 377–384382and imaging techniques applied.16 Li et al. applied MRI to 341 adult
patients with refractory focal epilepsy and found MCD in 12% of
cases.19 MCD represented 8% of partial epilepsy cases in Semah
et al.’s study.20 An incidence of 3% was found in Everitt et al.’s
prospective study.21 Furthermore, the prevalence of MCD could be
underestimated as a substantial proportion of patients, especially
those with cortical dysplasia, have negative MRI studies and can be
recognized only by a careful neuropathological study following
surgery.22 MCD rates near 25% have been reported in surgery
studies, the majority of cases with FCD.23,24 Due to the poor social
conditions that may predispose a person to gestational and
perinatal insults, it was hypothesized that the incidence of MCD
could be higher in a developing country such as was studied in this
report; however, this hypothesis is not conﬁrmed by our study.
The mean age of seizure onset in our study was at 12.3 years of
age, and the age of onset was found to occur as early as in the
neonatal period or as late as in middle age. Interestingly, we found
a case of epilepsy that started at 66 years of age with diagnosis of
FCD. Fausser et al. has similarly reported a patient with late
epilepsy onset at the age of 60.25 The mechanisms leading to
epileptogenesis in MCD are variable and are still under investiga-
tion. Similar to what is observed in other lesional epilepsies, the
structural anomaly may precede epilepsy onset by many years.
Moreover, epilepsy may never develop in a variable percentage of
patients according to the type of MCD.
In the present series, cases were classiﬁed according to BC.8–10
Seventy-one patients (51.4%) were diagnosed with malformations
due to abnormal cell proliferation (Group 1), 40 patients (28.9%)
had malformations due to abnormal migration (Group 2) and 27
patients (19.6%) had malformations due to abnormal cortical
organization (Group 3). We chose this classiﬁcation because it
allows patients to be categorized based on clinical and imaging
ﬁndings, without the need for genetic or histopathological studies.
Genetic tests in MCD are usually performed just for research
purposes and are not common in clinical settings, even in
developed countries.26–28
In our study, a comparative analysis of the 3 groups of MCD
showed that there was not a signiﬁcant difference in most of the
clinical and epidemiologic features; however, a signiﬁcant differ-
ence between these groups was noted in the presence of a focal
deﬁcit on the neurologic exam, which occurred more often in
Group 3, in which PMG and schizencephaly are included. Some
distinctive syndromes are well known in the spectrum of PMG. For
instance, bilateral perisylvian syndrome (see Fig. 3) is character-
ized by pseudobulbar palsy, cognitive deﬁcits, epilepsy and
bilateral perisylvian polymicrogyria on MRI.29 Other syndromes
in PMG have also been described.30–32 A high incidence of prenatal/
perinatal insults as a probable etiology of PMG and schizencephaly
has been reported in some studies.33,34 These insults could also be
the cause of the abnormalities found in the neurological exam.35
However, we did not ﬁnd a higher incidence of prenatal/perinatal
insults in Group 3 compared to the other groups. Variation in
localization or size of the lesions could be another reason for the
differences found in the neurological examination. For instance, all
of the 5 patients in Group 1 that presented with abnormal
neurological examinations (3 had FCD and 2 had TS) had large
lesions and multilobar involvement always affecting the periro-
landic region, whereas 85.5% of the patients without neurological
deﬁcit in this group (excluding those with TS that usually have
multifocal lesions) had a more circumscribed unilobar involve-
ment affecting the temporal or frontal lobes.
Relatively few large studies of adult patients with a diagnosis of
epilepsy and MCD have been reported. One example includes work
by Raymond et al.36 who analyzed 100 adults diagnosed with MCD,
with a mean age of 27 years, all of whom had refractory epilepsy. In
agreement with our ﬁndings, in this study, seizure onset was at amean age of ten, and epilepsy started in adulthood in only 30
patients. In contrast with our study, in which 100% of cases were
classiﬁed as having focal seizures, Raymond et al. described a
partial syndrome in 84% of their cases. These differing results could
be explained by the different classiﬁcations of seizures and
syndromes that were applied in both studies. Raymond et al. found
that 32% had a perinatal or prenatal insult, whereas in our series
this was found in 15.2% of cases. Mental retardation and
developmental delay were observed in 19% of cases, and
neurological deﬁcits were present in 14% in the Raymond patient
population. These ﬁndings are lower than what we found
(incidence of 31.9% and 21%, respectively) in our population.
Another study worth mentioning is Tinuper et al., which
included 60 patients:37 28% of the cases could not be classiﬁed
because of having a complex type of MCD (5 patients) or
incomplete medical data (12 patients). As in our study, the
Tinuper study used the BC to categorize the patients. To compare
with our ﬁndings, we had to recalculate the frequencies of the
subtypes described in this study, excluding the 17 patients that
were not classiﬁed. Following recalculation, the distribution in the
3 groups was as follows: 48.8% (21 patients) with a disorder in
proliferation, 39.5% (17 patients) with migration disorders, and
11.6% (5 patients) with abnormalities in organization. Likewise,
the majority of patients in our study were classiﬁed into Group 1
and Group 3 was the least frequent category.
Pascual-Castroviejo et al.38 presented 144 children classiﬁed
with the BC scheme. In this study, unlike in our study, the majority
(53.5%) of patients were included into Group 3, with 61 patients
with polymicrogyria and 16 patients with schizencephaly, whereas
they only found 9 cases with FCDs. They also included 22 patients
with lissencephaly and 8 cases with hemimegalencephaly; we did
not ﬁnd lissencephaly cases in our adult series, and we found 3
probable cases of hemimegalencephaly. These differences in the
distribution of the MCD subtypes could be explained because of the
variance in the ages of populations included in the studies
(pediatric vs. adults). Pediatric patient series of MCD are prone to
having a higher proportion of cases presenting epilepsy and
developmental delay and having more severe malformations such
as lissencephaly, hemimegalencephaly and extensive polymicro-
gyria and schizencephaly, whereas adult series, such as ours, tend
to include older patients with a higher percentage of focal cortical
dysplasias, low grade tumors, heterotopias and less severe
polymicrogyrias and schizencephalies. The usual coexistence of
neurological signs in Group 3 likely leads to an earlier consultation,
which could be one reason for the predominance of this group of
MCD in the pediatric series. Moreover, patients with severe
malformations like lissencephaly have a bad prognosis and usually
do not reach adulthood. This is reﬂected by the absence of this
subgroup in our study.
Montenegro et al. presented a study in a developing country
that took place in a center in Brazil,39 and Gu¨ngo¨r et al. have
presented a study based on patients in Turkey.40 Montenegro et al.
presented 100 patients with a diagnosis of MCD in a neuroimaging
study, but not all of the patients had epilepsy (epilepsy was present
in 77% of cases). Their most relevant ﬁnding was that epilepsy in
patients with polymicrogyria and schizencephaly had a better
control of seizures compared to the other groups. Similarly, Gu¨ngo¨r
et al. described 101 patients (of a pediatric population), in which
71.3% of cases with epilepsy. In this last study, it was also observed
that patients with polymicrogyria and schizencephaly had a better
control of their seizures. In contrast with these two last reports, our
study only included patients who had a conﬁrmed diagnosis of
epilepsy; our study did not ﬁnd a difference in seizure control
between the 3 groups of MCD. The high incidence of refractory
epilepsy in the 3 groups possibly reﬂects the fact that our study
was performed in a referral epilepsy center and that difﬁcult cases
C.E. Papayannis et al. / Seizure 21 (2012) 377–384 383are prone to be transferred to our center for their treatment and
follow up.
With regard to seizure types, all of our patients were considered
to have focal seizures. Just 6 patients had experienced epileptic
spasms or a diagnosis of West syndrome in their early infancy
developing focal seizures later during disease evolution. The
semiology of seizures was extremely variable. Temporal and
frontal lobe seizures seem to predominate in accordance with what
is published for focal epilepsies in the general population41 and
were observed in 29.7% and 28.3% of cases, respectively. Seizures
corresponding to more than one lobe occurred in 19.6% of the
cases. In Group 2, 35% of the cases (14 out of 40) showed seizures
with different onset corresponding to more than 1 lobe, whereas
this happened in only 9 out of 71 (12.7%) G1 cases and in only 4 out
of 27 G3 cases (14.8%). With respect to the localization and extent
of the lesions, multilobar involvement was higher in group 2 (71%;
10 out of 14 excluding PNH in which this concept cannot be
applied) and group 3 (62%; 17 out of 27), compared to group 1
(28%; 20 out of 71). We observed that seizure semiology depended
on the localization of the lesion and not on the type of MCD, as
different types of lesions in a given location showed the same
semiology.
EEG showed epileptiform discharges in 72.5% of all cases with
bilateral distribution in 54.9% of them. Bilateral discharges were
present in the following distribution: 46.5% of patients with
anomalies in proliferation, 40% of the patients with anomalies in
migration and 22.2% of patients with abnormalities in organiza-
tion. The differences found in the distribution of EEG discharges in
the different groups were not of statistical signiﬁcance. Video EEG
was performed in 29 patients (21%), and in 6 others (4.3%), video
EEG has been ordered but not performed yet. Patients that were
not considered good candidates for resective epilepsy surgery did
not have this test performed.
Most of the patients had medically refractory epilepsy; only 8
patients (5.7%) underwent epilepsy surgery. All the operated
patients belonged to Group 1, and there was agreement between
the presurgical image and the histopathological diagnosis. Many
developing countries have created epilepsy surgery programs in
recent years.42 However, a report from the year 2000 revealed that
only 26 out of 142 (18%) economically disadvantaged nations had
at least one center that regularly conducted epilepsy surgery,
compared with 18 out of 24 (75%) in developed countries.43
Moreover, epilepsy surgery centers in resource-poor countries, like
Argentina, lack the full range of state-of-the-art technologies to
perform presurgical evaluation and surgery techniques that are
usually available in developed countries.44 Very few patients in
resource-poor countries have access to or can afford the cost of the
intracranial electrodes that are used in invasive evaluation. In our
center, it is usual to perform surgery in patients with unilateral
mesial temporal lobe epilepsy or well-circumscribed lesions,
which do not need invasive or expensive techniques in the
presurgical evaluation, but this is not the case in the majority of
MCD patients. Nevertheless, MCD surgical outcome, even in the
developed world, is worse than that reported for HS and for other
focal pathologies. Large MCD studies with at least 2 years of follow
up suggest a 50–60% seizure-free outcome compared with 70–85%
in surgery for HS.45 This may reﬂect the incomplete understanding
of MCD biology and other non-biological issues that complicate
presurgical evaluation of these patients or the inadequate surgical
techniques applied. Completeness of resection, a key factor for
successful surgery, might be difﬁcult, especially in proximity to
eloquent cortex.46 Furthermore, there are cases in which surgery is
precluded beforehand, without even having an ordinary presurgi-
cal evaluation, as some subtypes of MCD are thought to be bad
candidates for surgery. This is the case for patients with bilateral,
extensive malformations or lesions localized in non-resectableeloquent areas. In our study, video EEG was not performed in these
cases, even if this technique was available, as they were not
considered for surgery. Regarding the different subtypes, FCD is
undoubtedly the most common MCD in surgical series. MCD
subtypes included in Group 2 and 3 are less likely to be considered
for surgery even in developed countries.45 Many of our cases in
Group 2 and 3 had bilateral or diffuse lesions in MRI.
The matters discussed above (limitations of presurgical
resources and poor risk-beneﬁt balance in determined cases)
explain the low proportion of patients in our study that underwent
surgery, even though the majority of our population was refractory
to medical treatment.
The present article is concerned with the clinical characteristics
found in a consecutive series of patients with epilepsy secondary to
MCD. It has to be considered that this is one of only a few studies on
this entity that have been carried out in a developing country. The
incidence rate that we found was similar to that reported in other
studies and does not differ from reports from developed countries.
Our study also reﬂects the usefulness of Barkovich et al.’s
classiﬁcation scheme in clinical practice, as we were able to divide
all patients in its 3 principal groups and make a comparison
between them. The only difference that we observed, when we
compared patients in the 3 groups, was that the presence of a
neurological deﬁcit was higher in patients belonging to Group 3
(cases with polymicrogyria and schizencephaly). When MCD is
suspected in an epileptic patient with an abnormal neurological
exam, these subtypes have to be thought as the ﬁrst diagnostic
possibility.
In a country with limited resources, the possibility of classifying
individual cases with imaging and electro clinical criteria alone,
without the need for genetic tests, is crucial for early diagnosis and
treatment. We think that the Barkovich classiﬁcation can be used
for correct categorization of patients with MCD and allows
physicians to make a prognosis and seek the best therapeutic
option for each case. For example, some cases with bilateral
pathology such as bilateral periventricular heterotopia, bilateral
perisylvian polymicrogyria or unilateral but extended malforma-
tions are not good surgical candidates. In this case, optimizing
medical treatment or other alternative therapeutic options (vagus
nerve stimulation, corpus callosotomy surgery or hemispherecto-
my) might be beneﬁcial.
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